Allergy Vaccines News and Research

RSS

Novel immunotherapy approach to revert the main hallmarks of cat allergy

Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system's allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy.

5 Feb 2021

Researchers develop promising allergy vaccine for hay fever

Using sugar molecules researchers from the University of Copenhagen have developed a new vaccine for hay fever that may reduce treatment times and increase the effect of treatments.

26 Sep 2018

VTT receives innovation prize for technological development work behind allergy vaccine

The European Association of Research and Technology Organisations EARTO has awarded VTT Technical Research Centre of Finland an innovation prize for the technological development work behind allergy vaccine.

5 Dec 2013

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Anergis, a company focusing on proprietary allergy vaccines, today reported immunology data from the Phase IIb study of its lead compound AllerT.

21 Oct 2013

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011

Researchers to develop house dust mite allergy vaccine that can cure asthma

Monash University researchers are working on a vaccine that could completely cure asthma brought on by house dust mite allergies.

22 Mar 2011

HAL Allergy files MAA for PURETHAL Mites and SUBLIVAC FIX products at Paul-Ehrlich-Institute

HAL Allergy today announced that it has filed marketing authorization applications (MAA) for PURETHAL(R) Mites and SUBLIVAC(R) FIX Grasses, Trees, and Mites (incl. homologous group products) at the Paul-Ehrlich-Institute, the regulatory authority in Germany.

29 Nov 2010

Circassia announces advancement in T-cell allergy vaccines development

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.

30 Sep 2010

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009